Henry Schein (NASDAQ:HSIC) CEO Sells $98,630.45 in Stock

Henry Schein, Inc. (NASDAQ:HSIC) CEO Thomas Popeck sold 1,355 shares of the company’s stock in a transaction that occurred on Thursday, March 19th. The shares were sold at an average price of $72.79, for a total value of $98,630.45. Following the sale, the chief executive officer owned 86,182 shares in the company, valued at approximately $6,273,187.78. This trade represents a 1.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Henry Schein Price Performance

Shares of Henry Schein stock opened at $72.24 on Monday. The stock has a market cap of $8.29 billion, a price-to-earnings ratio of 22.09, a price-to-earnings-growth ratio of 2.14 and a beta of 0.87. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.76 and a current ratio of 1.38. The stock has a 50 day moving average price of $77.72 and a 200-day moving average price of $73.06. Henry Schein, Inc. has a one year low of $60.56 and a one year high of $89.29.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.30 by $0.04. The company had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.34 billion. Henry Schein had a return on equity of 15.16% and a net margin of 3.02%.Henry Schein’s quarterly revenue was up 7.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.19 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Equities analysts expect that Henry Schein, Inc. will post 4.74 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on HSIC. Barrington Research set a $97.00 price target on shares of Henry Schein and gave the company an “outperform” rating in a report on Wednesday, February 25th. JPMorgan Chase & Co. raised their price objective on shares of Henry Schein from $78.00 to $92.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Morgan Stanley boosted their target price on Henry Schein from $58.00 to $61.00 and gave the company an “underweight” rating in a research report on Wednesday, February 25th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Henry Schein in a research note on Monday, December 29th. Finally, Mizuho increased their price target on Henry Schein from $81.00 to $88.00 and gave the stock a “neutral” rating in a report on Wednesday, February 25th. Six investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $85.58.

Institutional Trading of Henry Schein

A number of hedge funds have recently added to or reduced their stakes in HSIC. Hsbc Holdings PLC raised its holdings in shares of Henry Schein by 2.5% in the 4th quarter. Hsbc Holdings PLC now owns 123,550 shares of the company’s stock valued at $9,353,000 after purchasing an additional 3,014 shares in the last quarter. Reflection Asset Management bought a new position in shares of Henry Schein during the fourth quarter valued at approximately $516,000. Compound Planning Inc. purchased a new position in Henry Schein during the fourth quarter valued at approximately $275,000. Corient Private Wealth LLC increased its holdings in Henry Schein by 5.4% during the fourth quarter. Corient Private Wealth LLC now owns 37,019 shares of the company’s stock valued at $2,798,000 after buying an additional 1,906 shares during the period. Finally, Mercer Global Advisors Inc. ADV raised its stake in Henry Schein by 7.8% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 4,318 shares of the company’s stock worth $326,000 after buying an additional 312 shares in the last quarter. 96.62% of the stock is owned by hedge funds and other institutional investors.

More Henry Schein News

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Zacks raised its Q4 2027 EPS estimate to $1.62 from $1.44, signaling stronger expected back‑half performance for FY2027. Zacks note
• Positive Sentiment: Zacks boosted its Q3 2027 EPS to $1.49 from $1.42 and lifted FY2027 to $5.76 from $5.68, implying improved full‑year outlook beyond FY2026. Zacks note
• Positive Sentiment: Zacks nudged FY2026 guidance upward to $5.26 from $5.23 and raised Q3 2026 to $1.43 (from $1.39) and Q4 2026 to $1.44 (from $1.43), reflecting incremental improvement to near‑term full‑year estimates. Zacks note
• Neutral Sentiment: Zacks published an FY2028 EPS projection of $6.28 (new/forward‑looking estimate). This provides a growth runway but is not a direct revision to consensus today. Zacks note
• Negative Sentiment: Zacks cut its Q2 2027 EPS forecast to $1.38 from $1.47, a notable downgrade for the mid‑year quarter that may pressure near‑term expectations. Zacks note
• Negative Sentiment: Zacks trimmed Q1 2027 to $1.28 from $1.35 and lowered Q1 2026 to $1.20 from $1.22, indicating weaker near‑term quarterly visibility. Zacks note

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.